Aoxiang Pharmaceutical announced that its wholly-owned subsidiary Zhejiang Qizheng Pharmaceutical Co., Ltd. recently received the “Drug Registration Certificate” for rucotinib phosphate tablets approved and issued by the State Drug Administration. The specifications are 5 mg, 15 mg, and 20 mg. The drug approval numbers are Sinopharm H20265640, Sinopharm standard H20265641, and Sinopharm standard H20265642. This certification is considered to have passed the generic drug consistency evaluation.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.